Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: Dysfunction of mitochondrial energy generation may contribute to neurodegeneration, leading to synaptic loss in Parkinson's disease (PD). The objective of this study was to find cross‐sectional and longitudinal changes in PET markers of synaptic vesicle protein 2A, sigma 1 receptor, and mitochondrial complex 1 in drug‐naive PD patients. Methods: Twelve early drug‐naive PD patients and 16 healthy controls underwent a 3‐Tesla MRI and PET imaging to quantify volume of distribution of [11 C]UCB‐J, [11 C]SA‐4503, and [18 F]BCPP‐EF for synaptic vesicle protein 2A, sigma 1 receptor, and mitochondrial complex 1, respectively. Nine PD patients completed approximately 1‐year follow‐up assessments. Results: Reduced [11 C]UCB‐J volume of distribution in the caudate, putamen, thalamus, brain stem, and dorsal raphe and across cortical regions was observed in drug‐naive PD patients compared with healthy controls. [11 C]UCB‐J volume of distribution was reduced in the locus coeruleus and substantia nigra but did not reach statistical significance. No significant differences were found in [11 C]SA‐4503 and [18 F]BCPP‐EF volume of distribution in PD compared with healthy controls. Lower brain stem [11 C]UCB‐J volume of distribution correlated with Movement Disorder Society Unified Parkinson's Disease Rating Scale part III and total scores. No significant longitudinal changes were identified in PD patients at follow‐up compared with baseline. Conclusions: Our findings represent the first in vivo evidence of mitochondrial, endoplasmic reticulum, and synaptic dysfunction in drug‐naive PD patients. Synaptic dysfunction likely occurs early in disease pathophysiology and has relevance to symptomatology. Mitochondrial complex 1 and sigma 1 receptor pathology warrants further investigations in PD. Studies in larger cohorts with longer follow‐up will determine the validity of these PET markers to track disease progression. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Hayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease
Ryan, B. J., Hoek, S., Fon, E. A., & Wade-Martins, R. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.02.003 · Cited by 524 · cited 1×
“A common finding in animalmodels of PD as well as in brain tissue of patients with sporadic and familial forms of PD is the presence of histopathological evidence of progressive mitochondrial dysfunction.(23,24) Mitochondrial dysfunction is mainly characterized by the generation of reactive oxygen species, decreased M…”
BackgroundPark, J.-S., Davis, R. L., & Sue, C. M. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0829-3 · Cited by 516
Mitochondrial Dysfunction in Parkinson’s Disease
Moon, H. E., & Paek, S. H. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.2.103 · Cited by 455
Chen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J. W., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1836 · Cited by 431 · cited 1×
“We also evaluated [(11)C]UCB-J DVR-1 as an outcome measure, which is equivalent to [(11)C]UCB-J BPND previously reported.(44,60,61) Although [(11)C]UCB-J VT and [(11)C]UCB-J DVR-1 both showed consistent loss of SV2A, only changes in [(11)C]UCB-J VT survived FDR correction for multiple comparisons.”
MethodNabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296
SV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256 · cited 1×
“Synaptic vesicle protein 2A (SV2A) is a transmembrane protein widely expressed in presynaptic terminals throughout the brain, where it regulates neurotransmission.(4,5) Neurons lacking SV2A demonstrate impaired ability of vesicles to fuse with the plasma membrane.”
Background
Cited by
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
Imaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
Reduced Synaptic Density in Patients with Lewy Body Dementia: An [ 11 C ] UCB‐J PET Imaging Study
Andersen, K. B., Hansen, A. K., Damholdt, M. F., Horsager, J., Skjærbæk, C., Gottrup, H., Klit, H., Schacht, A. C., Danielsen, E. H., Brooks, D. J., et al. (2021) · Movement Disorders · doi:10.1002/mds.28617 · Cited by 84
“Finally, one study investigated 12 early PD patients and observed synaptic loss in the caudate, putamen, thalamus, brain stem, dorsal raphe, and across cortical regions.(30) Thus, several recent [(11)C] UCB-J studies have investigated synaptic loss in cohorts of PD patients with reduced binding in the SN being the mos…”
BackgroundSynaptic changes in psychiatric and neurological disorders: State-of-the art of in vivo imaging
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01943-x · Cited by 34
“The substantia nigra, a key nucleus in the pathophysiology of PD, showed signi fi cantly lower tracer uptake in three studies [93, 97, 98], while Wilson et al. [95] found changes in the dorsal raphe nuclei and the brainstem.”
BackgroundResultInfluentialVisser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
“All but two study corrected for Partial Volume Effects (PVEs, Coomans et al., 2021; Wilson et al., 2020).”
BackgroundResultInfluentialRaval, N. R., Gudmundsen, F., Juhl, M., Andersen, I. V., Speth, N., Videbæk, A., Petersen, I. N., Mikkelsen, J. D., Fisher, P. M., Herth, M. M., et al. (2021) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.715811 · Cited by 22
Halff, E. F., Cotel, M.-C., Natesan, S., McQuade, R., Ottley, C. J., Srivastava, D. P., Howes, O. D., & Vernon, A. C. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113203 · Cited by 18
Drake, L. R., Wu, Y., Naganawa, M., Asch, R., Zheng, C., Najafzadeh, S., Pracitto, R., Lindemann, M., Li, S., Ropchan, J., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266470 · Cited by 18
Metadata
- Authors
- Wilson, H., Pagano, G., de Natale, E. R., Mansur, A., Caminiti, S. P., Polychronis, S., Middleton, L. T., Price, G., Schmidt, K. F., Gunn, R. N., Rabiner, E. A., & Politis, M.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2020-04-29
- Volume
- 35
- Issue
- 8
- Pages
- 1416-1427
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W3020259799
- Cited by
- 80
- References
- 14
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.